Xarelto 20mg 100 tablets — Made in Germany — Free Delivery

Product description

Xarelto® tablets are used for the following indications:

• prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation and one or more risk factors, such as congestive heart failure, arterial hypertension, age ≥ 75 years, diabetes mellitus, stroke, or a history of transient ischemic attack;
• treatment of deep vein thrombosis (DVT), pulmonary embolism (PE) and prevention of recurrence of DVT and PE in adults.

Structure

The active ingredient is rivaroxaban (one coated tablet contains 20 mg of rivaroxaban).

Excipients: microcrystalline cellulose, sodium croscarmellose, hypromellose 5 cf, hypromellose 15 cf, lactose monohydrate, magnesium stearate, sodium lauryl sulfate, macrogol 3350, titanium dioxide (E 171), iron oxide red (E 172).

Contraindications

Hypersensitivity to rivaroxaban or to any excipients of the preparation.

Clinically significant active bleeding.

Injury or conditions with a significant risk of bleeding, which include currently or recently diagnosed ulcers of the gastrointestinal tract, malignant tumors with a high risk of bleeding, recent brain or spinal cord injury, recent surgery on the brain, spinal cord or eyes, recent intracranial hemorrhage, esophageal varices (detected or suspected), arteriovenous malformations, vascular aneurysms, or significant intraspinal or intracerebral vascular abnormalities.

Simultaneous use with any other anticoagulants, in particular with unfractionated heparin, low molecular weight heparins (enoxaparin, dalteparin and others), heparin derivatives (fondaparinux and others), oral anticoagulants (warfarin, dabigatran etexilate and others), except for the transition to specific circumstances anticoagulant therapy or cases where unfractionated heparin is prescribed in doses necessary for the functioning of an open catheter of the central veins or arteries.

Liver diseases associated with coagulopathy and a clinically significant risk of bleeding, including class B and C liver cirrhosis (according to the Child-Pugh classification).

The patient's age is up to 18 years.

During pregnancy and breastfeeding.

Mode of application

Prevention of stroke and systemic embolism

It is recommended to prescribe 1 tablet "Xarelto®" 20 mg once a day, this dose is also the maximum recommended dose.

Treatment with Xarelto® should be continued for a long time, provided that the benefits of preventing stroke and systemic embolism outweigh the risk of bleeding.

In case of missed pill intake, the patient should take Xarelto® immediately and the next day continue treatment with taking 1 time per day at the recommended dosage. Do not take a double dose on the same day to make up for a missed pill.

Treatment of DVT, PE and prevention of recurrence of DVT and PE

During the first 3 weeks for the treatment of acute DVT and PE, it is recommended to prescribe one Xarelto® tablet 15 mg twice a day, after which - 20 mg Xarelto® once a day for long-term treatment and prevention of DVT recurrence and TELA.

Short-term therapy (at least 3 months) should be given to patients with DVT or PE in the presence of transient risk factors (such as recent surgery or trauma). Long-term therapy should be given to patients with DVT or PE that are not associated with transient risk factors, idiopathic DVT or PE, or a history of DVT or PE.

When prolonged prophylaxis of recurrent DVT or PE is indicated (after completion of DVT and PE therapy for at least 6 months), the recommended dose is 10 mg once daily. For patients with a high risk of recurrent DVT or PE, with complicated concomitant diseases, as well as for patients who have had a relapse of DVT or PE while using the preparation "Xarelto®" 10 mg once a day, for prophylaxis, it may be advisable to use the preparation Xarelto® 20 mg once a day.

The duration of treatment is determined individually after a careful assessment of the benefits of the application and the potential risk of bleeding.

The introductory part of the instructions is given, read the full instructions inside the package.

Application features

Drivers

"Xarelto®" has an insignificant effect on the ability to drive vehicles or other mechanisms. Adverse reactions have been reported such as cases of syncope (frequency: infrequent) or dizziness (frequency: common).

Patients who experience this type of adverse reaction should not drive or operate machinery.

Overdose

There have been rare cases of overdose (up to 600 mg) without complications such as bleeding or other adverse reactions. Due to limited absorption, when the preparation is administered at doses significantly higher than therapeutic doses (50 mg or higher), a satiety effect is expected without further increase in mean plasma level.

There is a specific neutralizing agent (andexanet alfa) that counteracts the pharmacological effects of rivaroxaban. In case of preparation overdose, activated charcoal can be used to reduce the absorption of rivaroxaban.

Side effects

The most common reported adverse reactions in patients receiving rivaroxaban were bleeding. There were frequent reports of nosebleeds (4.5%) and bleeding from the gastrointestinal tract (3.8%).

Storage conditions

Store at a temperature not exceeding 30 ° C, out of the reach of children.

Shelf life is 3 years.